# Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

> **NCT03251144** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 26 (actual)

## Conditions studied

- HIV/AIDS
- Antiviral Toxicity
- Antiviral Drug Adverse Reaction
- Mitochondrial Alteration

## Interventions

- **DRUG:** Switch to E/C/FTC/TAF daily

## Key facts

- **NCT ID:** NCT03251144
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251144, "Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03251144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*